APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diabetic Gastroparesis Treatment

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.

During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system.

Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.

Selected research

Market Analysis & Forecast

Global Diabetic Gastroparesis Treatment Market Analysis and Forecast 2026-2032

28 December 2025198 pages

Choose your research edition.

Industry ResearchDiabetic Gastroparesis Treatment Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Diabetic Gastroparesis Treatment Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Diabetic Gastroparesis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diabetic Gastroparesis Treatment Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Diabetic Gastroparesis Treatment Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

Diabetic gastroparesis refers to cases of the digestive condition gastroparesis that diabetes causes.

During normal digestion, the stomach contracts to help break down food and move it into the small intestine. Gastroparesis disrupts the stomach’s contraction, which can interrupt digestion. Diabetes can cause gastroparesis due to its effects on the nervous system.

Both type 1 diabetes and type 2 diabetes can cause nerve damage. One of the nerves diabetes may damage is the vagus nerve. The vagus nerve controls the movement of food through the stomach. When the vagus nerve experiences damage, the muscles in the stomach and other parts of the digestive tract are not able to function properly. When this happens, food cannot move as quickly through the digestive system. Gastroparesis is also known as delayed gastric emptying.

Read the full market overview

Market is not concentrated. Sumitomo, Johnson & Johnson, Sanofi are the leaders of the industry, and hold the key technologies and patent, with high-end customers. Top 3 manufacturer accounted for 7.4% market share in 2019.

Report Includes

This report presents an overview of global market for Diabetic Gastroparesis Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Diabetic Gastroparesis Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Diabetic Gastroparesis Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Diabetic Gastroparesis Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Diabetic Gastroparesis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Diabetic Gastroparesis Treatment revenue, projected growth trends, production technology, application and end-user industry.

Diabetic Gastroparesis Treatment Segment by Company

Sumitomo

Johnson & Johnson

Sanofi

Medtronic

Pfizer

Teva

Boston Scientific

Diabetic Gastroparesis Treatment Segment by Type

Drugs

Surgical Treatment Products

Diabetic Gastroparesis Treatment Segment by Application

Hospital Pharmacies

Private Clinics

Drug Stores

E-Commerce

Diabetic Gastroparesis Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetic Gastroparesis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diabetic Gastroparesis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetic Gastroparesis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Diabetic Gastroparesis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Diabetic Gastroparesis Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diabetic Gastroparesis Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Diabetic Gastroparesis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Drugs Major Player Table 3. Surgical Treatment Products Major Player Table 4. Global Diabetic Gastroparesis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Pharmacies Major Player Table 6. Private Clinics Major Player Table 7. Drug Stores Major Player Table 8. E-Commerce Major Player Table 9. Diabetic Gastroparesis Treatment Industry Trends Table 10. Diabetic Gastroparesis Treatment Industry Drivers Table 11. Diabetic Gastroparesis Treatment Industry Opportunities and Challenges Table 12. Diabetic Gastroparesis Treatment Industry Restraints Table 13. Global Diabetic Gastroparesis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Diabetic Gastroparesis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Diabetic Gastroparesis Treatment Market Share by Region (2021-2026) Table 16. Global Diabetic Gastroparesis Treatment Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Diabetic Gastroparesis Treatment Market Share by Region (2027-2032) Table 18. Global Diabetic Gastroparesis Treatment Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Diabetic Gastroparesis Treatment Revenue Market Share by Players (2021-2026) Table 20. Global Diabetic Gastroparesis Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Diabetic Gastroparesis Treatment Key Players Headquarters & Area Served Table 22. Global Diabetic Gastroparesis Treatment Players, Product Type & Application Table 23. Global Diabetic Gastroparesis Treatment Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Diabetic Gastroparesis Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Diabetic Gastroparesis Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Diabetic Gastroparesis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Diabetic Gastroparesis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Diabetic Gastroparesis Treatment Revenue Market Share by Type (2021-2026) Table 30. Global Diabetic Gastroparesis Treatment Revenue Market Share by Type (2027-2032) Table 31. Global Diabetic Gastroparesis Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Diabetic Gastroparesis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Diabetic Gastroparesis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Diabetic Gastroparesis Treatment Revenue Market Share by Application (2021-2026) Table 35. Global Diabetic Gastroparesis Treatment Revenue Market Share by Application (2027-2032) Table 36. Sumitomo Company Information Table 37. Sumitomo Business Overview Table 38. Sumitomo Diabetic Gastroparesis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sumitomo Diabetic Gastroparesis Treatment Product Portfolio Table 40. Sumitomo Recent Development Table 41. Johnson & Johnson Company Information Table 42. Johnson & Johnson Business Overview Table 43. Johnson & Johnson Diabetic Gastroparesis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Johnson & Johnson Diabetic Gastroparesis Treatment Product Portfolio Table 45. Johnson & Johnson Recent Development Table 46. Sanofi Company Information Table 47. Sanofi Business Overview Table 48. Sanofi Diabetic Gastroparesis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Sanofi Diabetic Gastroparesis Treatment Product Portfolio Table 50. Sanofi Recent Development Table 51. Medtronic Company Information Table 52. Medtronic Business Overview Table 53. Medtronic Diabetic Gastroparesis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Medtronic Diabetic Gastroparesis Treatment Product Portfolio Table 55. Medtronic Recent Development Table 56. Pfizer Company Information Table 57. Pfizer Business Overview Table 58. Pfizer Diabetic Gastroparesis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer Diabetic Gastroparesis Treatment Product Portfolio Table 60. Pfizer Recent Development Table 61. Teva Company Information Table 62. Teva Business Overview Table 63. Teva Diabetic Gastroparesis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Teva Diabetic Gastroparesis Treatment Product Portfolio Table 65. Teva Recent Development Table 66. Boston Scientific Company Information Table 67. Boston Scientific Business Overview Table 68. Boston Scientific Diabetic Gastroparesis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Boston Scientific Diabetic Gastroparesis Treatment Product Portfolio Table 70. Boston Scientific Recent Development Table 71. North America Diabetic Gastroparesis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 72. North America Diabetic Gastroparesis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 73. North America Diabetic Gastroparesis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 74. North America Diabetic Gastroparesis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 75. North America Diabetic Gastroparesis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 76. North America Diabetic Gastroparesis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 77. North America Diabetic Gastroparesis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 78. Europe Diabetic Gastroparesis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 79. Europe Diabetic Gastroparesis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 80. Europe Diabetic Gastroparesis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 81. Europe Diabetic Gastroparesis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 82. Europe Diabetic Gastroparesis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 83. Europe Diabetic Gastroparesis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 84. Europe Diabetic Gastroparesis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 85. China Diabetic Gastroparesis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 86. China Diabetic Gastroparesis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 87. China Diabetic Gastroparesis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 88. China Diabetic Gastroparesis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 89. Asia Diabetic Gastroparesis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 90. Asia Diabetic Gastroparesis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 91. Asia Diabetic Gastroparesis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 92. Asia Diabetic Gastroparesis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 93. Asia Diabetic Gastroparesis Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 94. Asia Diabetic Gastroparesis Treatment Revenue by Region (US$ Million) & (2021-2026) Table 95. Asia Diabetic Gastroparesis Treatment Revenue by Region (US$ Million) & (2027-2032) Table 96. SAMEA Diabetic Gastroparesis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 97. SAMEA Diabetic Gastroparesis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 98. SAMEA Diabetic Gastroparesis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 99. SAMEA Diabetic Gastroparesis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 100. SAMEA Diabetic Gastroparesis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 101. SAMEA Diabetic Gastroparesis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 102. SAMEA Diabetic Gastroparesis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Diabetic Gastroparesis Treatment Image Figure 2. Global Diabetic Gastroparesis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diabetic Gastroparesis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Drugs Image Figure 5. Surgical Treatment Products Image Figure 6. Global Diabetic Gastroparesis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Diabetic Gastroparesis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Pharmacies Image Figure 9. Private Clinics Image Figure 10. Drug Stores Image Figure 11. E-Commerce Image Figure 12. Global Diabetic Gastroparesis Treatment Market Size (US$ Million) & (2021-2032) Figure 13. Global Diabetic Gastroparesis Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Diabetic Gastroparesis Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Diabetic Gastroparesis Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Diabetic Gastroparesis Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Diabetic Gastroparesis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Diabetic Gastroparesis Treatment Revenue Market Share by Type (2021-2032) Figure 20. Global Diabetic Gastroparesis Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Diabetic Gastroparesis Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Diabetic Gastroparesis Treatment Revenue Market Share by Application (2021-2032) Figure 23. North America Diabetic Gastroparesis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032) Figure 25. North America Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032) Figure 26. North America Diabetic Gastroparesis Treatment Revenue Share by Country (2021-2032) Figure 27. United States Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Diabetic Gastroparesis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032) Figure 32. Europe Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032) Figure 33. Europe Diabetic Gastroparesis Treatment Revenue Share by Country (2021-2032) Figure 34. Germany Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Diabetic Gastroparesis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032) Figure 44. China Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032) Figure 45. Asia Diabetic Gastroparesis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032) Figure 47. Asia Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Diabetic Gastroparesis Treatment Revenue Share by Region (2021-2032) Figure 49. Japan Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Diabetic Gastroparesis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032) Figure 57. SAMEA Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032) Figure 58. SAMEA Diabetic Gastroparesis Treatment Revenue Share by Country (2021-2032) Figure 59. Brazil Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Diabetic Gastroparesis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Drugs
  • Surgical Treatment Products
Applications
  • Hospital Pharmacies
  • Private Clinics
  • Drug Stores
  • E-Commerce
Companies covered
  • Sumitomo
  • Johnson & Johnson
  • Sanofi
  • Medtronic
  • Pfizer
  • Teva
  • Boston Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Diabetic Gastroparesis Treatment Market by Type
  3. 1.2.1 Global Diabetic Gastroparesis Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Drugs
  5. 1.2.3 Surgical Treatment Products
  6. 1.3 Diabetic Gastroparesis Treatment Market by Application
  7. 1.3.1 Global Diabetic Gastroparesis Treatment Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital Pharmacies
  9. 1.3.3 Private Clinics
  10. 1.3.4 Drug Stores
  11. 1.3.5 E-Commerce
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Diabetic Gastroparesis Treatment Market Dynamics
  1. 2.1 Diabetic Gastroparesis Treatment Industry Trends
  2. 2.2 Diabetic Gastroparesis Treatment Industry Drivers
  3. 2.3 Diabetic Gastroparesis Treatment Industry Opportunities and Challenges
  4. 2.4 Diabetic Gastroparesis Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Diabetic Gastroparesis Treatment Market Perspective (2021-2032)
  2. 3.2 Global Diabetic Gastroparesis Treatment Growth Trends by Region
  3. 3.2.1 Global Diabetic Gastroparesis Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Diabetic Gastroparesis Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Diabetic Gastroparesis Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Diabetic Gastroparesis Treatment Revenue by Players
  2. 4.1.1 Global Diabetic Gastroparesis Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Diabetic Gastroparesis Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Diabetic Gastroparesis Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Diabetic Gastroparesis Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Diabetic Gastroparesis Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Diabetic Gastroparesis Treatment Players, Product Type & Application
  8. 4.5 Global Diabetic Gastroparesis Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Diabetic Gastroparesis Treatment Market CR5 and HHI
  11. 4.6.3 2025 Diabetic Gastroparesis Treatment Tier 1, Tier 2, and Tier 3
5 Diabetic Gastroparesis Treatment Market Size by Type
  1. 5.1 Global Diabetic Gastroparesis Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Diabetic Gastroparesis Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Diabetic Gastroparesis Treatment Revenue Market Share by Type (2021-2032)
6 Diabetic Gastroparesis Treatment Market Size by Application
  1. 6.1 Global Diabetic Gastroparesis Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Diabetic Gastroparesis Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Diabetic Gastroparesis Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sumitomo
  2. 7.1.1 Sumitomo Company Information
  3. 7.1.2 Sumitomo Business Overview
  4. 7.1.3 Sumitomo Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sumitomo Diabetic Gastroparesis Treatment Product Portfolio
  6. 7.1.5 Sumitomo Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Diabetic Gastroparesis Treatment Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Diabetic Gastroparesis Treatment Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Medtronic
  20. 7.4.1 Medtronic Company Information
  21. 7.4.2 Medtronic Business Overview
  22. 7.4.3 Medtronic Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Medtronic Diabetic Gastroparesis Treatment Product Portfolio
  24. 7.4.5 Medtronic Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Diabetic Gastroparesis Treatment Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Teva
  32. 7.6.1 Teva Company Information
  33. 7.6.2 Teva Business Overview
  34. 7.6.3 Teva Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Teva Diabetic Gastroparesis Treatment Product Portfolio
  36. 7.6.5 Teva Recent Developments
  37. 7.7 Boston Scientific
  38. 7.7.1 Boston Scientific Company Information
  39. 7.7.2 Boston Scientific Business Overview
  40. 7.7.3 Boston Scientific Diabetic Gastroparesis Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Boston Scientific Diabetic Gastroparesis Treatment Product Portfolio
  42. 7.7.5 Boston Scientific Recent Developments
8 North America
  1. 8.1 North America Diabetic Gastroparesis Treatment Revenue (2021-2032)
  2. 8.2 North America Diabetic Gastroparesis Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Diabetic Gastroparesis Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Diabetic Gastroparesis Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Diabetic Gastroparesis Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Diabetic Gastroparesis Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Diabetic Gastroparesis Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Diabetic Gastroparesis Treatment Revenue by Country
  11. 8.6.1 North America Diabetic Gastroparesis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Diabetic Gastroparesis Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Diabetic Gastroparesis Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Diabetic Gastroparesis Treatment Revenue (2021-2032)
  2. 9.2 Europe Diabetic Gastroparesis Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Diabetic Gastroparesis Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Diabetic Gastroparesis Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Diabetic Gastroparesis Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Diabetic Gastroparesis Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Diabetic Gastroparesis Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Diabetic Gastroparesis Treatment Revenue by Country
  11. 9.6.1 Europe Diabetic Gastroparesis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Diabetic Gastroparesis Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Diabetic Gastroparesis Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Diabetic Gastroparesis Treatment Revenue (2021-2032)
  2. 10.2 China Diabetic Gastroparesis Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Diabetic Gastroparesis Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Diabetic Gastroparesis Treatment Revenue by Type (2027-2032)
  5. 10.3 China Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Diabetic Gastroparesis Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Diabetic Gastroparesis Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Diabetic Gastroparesis Treatment Revenue by Application (2027-2032)
  9. 10.5 China Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Diabetic Gastroparesis Treatment Revenue (2021-2032)
  2. 11.2 Asia Diabetic Gastroparesis Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Diabetic Gastroparesis Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Diabetic Gastroparesis Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Diabetic Gastroparesis Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Diabetic Gastroparesis Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Diabetic Gastroparesis Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Diabetic Gastroparesis Treatment Revenue by Country
  11. 11.6.1 Asia Diabetic Gastroparesis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Diabetic Gastroparesis Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Diabetic Gastroparesis Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Diabetic Gastroparesis Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Diabetic Gastroparesis Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Diabetic Gastroparesis Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Diabetic Gastroparesis Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Diabetic Gastroparesis Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Diabetic Gastroparesis Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Diabetic Gastroparesis Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Diabetic Gastroparesis Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Diabetic Gastroparesis Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Diabetic Gastroparesis Treatment Revenue by Country
  11. 12.6.1 SAMEA Diabetic Gastroparesis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Diabetic Gastroparesis Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Diabetic Gastroparesis Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst